Suchen
Chemomab Therapeutics Ltd
CMMBZur Watchlist hinzufügen
2.270USD
+0.550+31.98%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
65.38MMarktkapitalisierung
13.03KGV TTM
mehr Informationen über Chemomab Therapeutics Ltd Unternehmen
Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Chemomab Therapeutics Ltd Informationen
BörsenkürzelCMMB
Name des UnternehmensChemomab Therapeutics Ltd
IPO-datumAug 14, 2012
CEOMor (Adi)
Anzahl der mitarbeiter16
WertpapierartDepository Receipt
GeschäftsjahresendeAug 14
AddresseKiryat Atidim, Building 7
StadtTEL AVIV-YAFO
BörseNASDAQ OMX - NASDAQ BASIC
LandIsrael
Postleitzahl6158002
Telefon972773310156
Websitehttps://www.chemomab.com/
BörsenkürzelCMMB
IPO-datumAug 14, 2012
CEOMor (Adi)
Führungskräfte von Chemomab Therapeutics Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
14.48K
+95.59%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
300.00
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Adi Mor, Ph.D.
Dr. Adi Mor, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Investor Relations
Investor Relations
--
--
Dr. David M. Weiner, M.D.
Dr. David M. Weiner, M.D.
Interim Chief Medical Officer
Interim Chief Medical Officer
--
--
Mr. Jack Lawler
Mr. Jack Lawler
Chief Development Officer
Chief Development Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
14.48K
+95.59%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
300.00
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Adi Mor, Ph.D.
Dr. Adi Mor, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Chemomab Therapeutics Ltd?
Die fünf größten Anteilseigner von Chemomab Therapeutics Ltd sind: Ms. Sigal Fattal, CPA
Wie viele Institutionen halten Anteile an Chemomab Therapeutics Ltd (CMMB)?
Mit Stand vom 2026Q1 halten 33 Institutionen Anteile an Chemomab Therapeutics Ltd, mit einem Gesamtmarktwert von etwa 402.96K, was 5.60% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -450971.00 gestiegen.